Effects of Metformin on the Cerebral Metabolic Changes in Type 2 Diabetic Patients

Table 1

Patient characteristics.

	MET (𝑛=18)	wdMET (𝑛=13)	noMET (𝑛=9)
Gender (M : F)	8 : 10	9 : 4	6 : 3
Age (years)	63.8±7.1	58.7±8.3	60.8±5.6
BMI (kg/m^2)	25.8±3.4	26.5±2.4	27.7±5.5
HbA1c (%)	7.0±1.0	7.1±1.1	6.3±0.7
Fasting blood sugar (mmol/L)	7.5±1.4	7.3±1.1	7.4±1.4
Metformin daily dose (mg)	1194±546	1058±560	—
Diabetes duration (years)	8.2±7.1	7.9±8.2	7.1±9.0
y < 5 : y ≥ 5	7 : 11	8 : 5	5 : 4
MMSE score	25.6±4.3	27.0±2.2	27.0±2.9
Education (years)	9.7±6.4	9.9±6.2	10.4±5.1
Current smoker	1	2	2

Values are means ± standard deviation or numeric proportions, as indicated. MET: patients taking metformin; wdMET: patients withdrawing from metformin for more than 3 days; noMET: patients not taking metformin; BMI: body mass index; HbA_1c: glycated hemoglobin; MMSE: Mini-Mental State Examination. There were no significant differences between the three groups (all 𝑃>0.05).